P053 Pro-resolution Pathway in Experimental Colitis – A New Possible Therapeutic Approach for Inflammatory Bowel Diseases
F H M Chaim,L B Pascoal,B B Palma,B L Rodrigues,M M Castro,J J Fagundes,M Milanski,L R Lopes,L A Velloso,R F Leal
DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0183
2024-01-01
Journal of Crohn's and Colitis
Abstract:Abstract Background Inflammatory bowel diseases (IBD) are idiopathic disorders characterized by chronic inflammation of the gastrointestinal tract. New therapeutic strategies involving the inflammatory process are being proposed because the usual therapies indicated for IBD may cause adverse reactions and clinical failure. Recent studies have highlighted the role of specialized pro-resolution lipid mediators (SPMs) in the active resolution of chronic inflammation. Therefore, this study aimed to investigate the SPM Resolvin D2 (RvD2) and its precursor, omega-3 polyunsaturated fatty acid, in experimental colitis induced by dextran sulfate sodium (DSS). Methods An experimental model with male mice of the C57BL/6J lineage was carried out. Mice were separated into a control group, and a DSS-induced colitis group (3% dilution in drinking water); both groups were subdivided and received either a standard diet or an experimental diet enriched with 20% of oil rich in omega-3. Another group of mice, after acquiring experimental DSS-induced colitis, was subdivided and treated with RvD2 or anti-TNFα. Throughout the experimental protocols, the body weight, food intake, Disease Activity Index (DAI), metabolic phenotype, and inflammatory profile of these animals were assessed by real-time PCR, ELISA, histology, Western blotting, and lipid analysis. The study was approved by the University of Campinas research ethics committee. Results The animals with experimental colitis induced by DSS showed an increase in TNFα and IL22 transcriptional expression besides a reduction in the enzymes involved in the endogenous biosynthesis of RvD2, such as PLA2, 15-LOX, 5-LOX, and its receptor GPR18. Dietary supplementation with omega-3-rich oil increased RvD2 and its precursor besides reducing the DAI, weight loss, colonic shortening, and the histologic colonic inflammation score. Treatment with RvD2 effectively attenuated experimental colitis, reducing TNFα transcriptional levels and p-JNK protein expression. Besides, RvD2 increased the immediate precursor of RvD2 (7,8-epoxy-17-HDHA). All of which indicates that this pathway is responsible for the observed effects. Conclusion Our study provided a better understanding of the molecular mechanisms involved in the exacerbated inflammatory response present in colitis. The beneficial effect of RvD2 and its precursor omega-3 may bring about a new therapeutic approach for IBD.
gastroenterology & hepatology